The Changing Climate of Vector-Borne Diseases
The consequences of climate change are now readily visible worldwide. Driven primarily by greenhouse gases released into the atmosphere by human activities such as the burning of fossil fuels, average global temperatures for the past decade have been the warmest in recorded history.1 Current trends are expected to persist, with global average temperatures estimated to […]
Widespread Beta-Lactamase Resistance Genes Pose Growing Threat Across One Health Domains in the US
Babafela Awosile, DVM, MVSc, PhD, DACVPM Image credits: LinkedIn A comprehensive review of research underscores the widespread distribution of beta-lactamase resistance genes in Enterobacteriaceae across human, animal, and environmental sources in the United States. The study, which analyzed 335 articles published between 1981 and April 2022, provides critical insights into the molecular epidemiology of these […]
Estimating the AUC for Vancomycin Using Non Trapezoidal Equations
In the first part of the interview with Msdi, he discussed AUC-based monitoring for vancomycin and its adoption by institutions and its value in dosing. (See the article below.) Read more: Looking at the Slow Adoption of AUC-Based Monitoring for Vancomycin In this segment, Msdi talks about using a unique approach that estimates the AUC […]
Do We Have New Data for Optimal Treatments of Candida-Related Prosthetic Joint Infections?
Prosthetic joint infections (PJIs) are among the most common complications of arthroplasties. Most PJIs are caused by bacteria and most commonly by Staphylococcus species, whereas only 1% to 2% are caused by fungi.1 Among these rare fungal PJIs, Candida species are the most isolated pathogens, with Candida albicans being the most prevalent, followed by non–C […]
Exploiting Zinc Limitation to Combat Carbapenem-Resistant Bacteria
Megan M Tu, PhD Candidate, McMaster University Image credits: LinkedIn Carbapenems, the last line of defense against serious bacterial infections, are increasingly ineffective against pathogens that produce metallo-β-lactamases (MBLs) such as VIM-2. These enzymes enable bacteria to resist carbapenem treatment, and there are currently no approved inhibitors targeting these enzymes in clinical settings. Although, recent […]
Looking at the Slow Adoption of AUC-Based Monitoring for Vancomycin
The development of the AUC-based vancomycin monitoring guidelines published in 2020 by the Infectious Diseases Society of America provided an updated foundation for clinicians and institutions to begin to utilize it, but there is a lot of nuance that needs to be considered when utilizing it. Implementation of AUC-based vancomycin monitoring nationwide is moving in […]
Targeting C difficile with Oxygen-Based Therapy
LPOXY Therapeutics, Inc has acquired key assets from Xeno Biosciences Inc to advance its therapy, SIDIPREV, aimed at preventing Clostridioides difficile (C difficile) infections in hospitalized patients. The acquisition includes regulatory filings, FDA correspondence, CMC data, intellectual property, and Phase I and Ib clinical trial data confirming the safety of the active pharmaceutical ingredient. This […]
Another Case of Shorter Is Better?
The optimal duration of antibiotic therapy for Streptococcus pneumoniae bacteremia remains a topic of debate in clinical practice. The mortality rate of bacteremia associated with a pneumococcal infection ranges from 6% to 20%.1 Balancing effective treatment with the need to minimize antibiotic exposure is critical, as prolonged courses can contribute to increased risk of Clostridioides […]
COVID-19 Infection Does Not Impact Symptom Severity or Disability Trajectory in Multiple Sclerosis
This article was originally published on our sister site, NeurologyLive. Using a controlled interrupted time series (ITS), a quasiexperimental study design, researchers found that COVID-19 infection was not associated with immediate changes in symptom severity or disability in patients with multiple sclerosis (MS), nor did it change the trajectories of these outcomes over a median […]
Treatment With Ziresovir in Infants
The fall and winter months signal an increase in viral infections circulating among children and families, including influenza, COVID-19, and respiratory syncytial virus (RSV). Although RSV is a public health concern for individuals of all ages, infants and toddlers, especially those born prematurely or with compromised immune systems, and older individuals have particular vulnerability to […]
